Drug Profile
Tumour cells apoptosis factor - Immune System Key
Alternative Names: 84AA–API 14AA; NerofeLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Immune System Key
- Developer Immune System Key; University of Miami
- Class Antineoplastics; Cardiovascular therapies; Peptide hormones
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Interleukin 1 receptor-like 1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase I/II Ovarian cancer; Triple negative breast cancer
- Phase I Solid tumours
- Discontinued Myocardial infarction
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy) in USA (IV, Infusion)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
- 01 Feb 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT05661201)